180
Views
5
CrossRef citations to date
0
Altmetric
Original Article: Research

Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid

, , &
Pages 966-973 | Received 01 Jan 2009, Accepted 02 Mar 2009, Published online: 21 Jul 2009
 

Abstract

Activation of PPARγ by its ligands has shown differentiating effects in solid tumors. However, few reports addressed its role in myeloma cells. Our study demonstrated that exposure to PPARγ ligand (rosiglitazone, RGZ) induced proliferation inhibition and cell cycle arrest in myeloma cells. A combination of RGZ with all-trans retinoic acid (ATRA) can enhance the growth inhibition effects of RGZ. Further study shows that RGZ-treated myeloma cells displayed morphological characteristics of cell differentiation, and more evident signs of differentiation were observed when RGZ was combined with ATRA. These changes were confirmed by the detection of CD49e expression and light chain protein secretion. Similar results were also observed when primary CD138+ cells were treated with RGZ and ATRA. Collectively, our study revealed that RGZ can induce cell differentiation in myeloma cells and concomitant treatment with ATRA can enhanced the effects of RGZ.

View retraction statement:
Statement of Retraction: Huang H, Wu D, Fu J, Chen G. “Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid”

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.